Theratechnologies Ebitda from 2010 to 2024

THTX Stock  USD 1.40  0.15  9.68%   
Theratechnologies EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -12.5 M in 2024. During the period from 2010 to 2024, Theratechnologies EBITDA regression line of annual values had significance of  0.03 and arithmetic mean of (7,170,247). View All Fundamentals
 
EBITDA  
First Reported
1997-02-28
Previous Quarter
M
Current Value
6.6 M
Quarterly Volatility
5.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theratechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theratechnologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Total Revenue of 98.7 M or Gross Profit of 75 M, as well as many indicators such as Price To Sales Ratio of 0.56, Dividend Yield of 0.0 or Days Sales Outstanding of 62.42. Theratechnologies financial statements analysis is a perfect complement when working with Theratechnologies Valuation or Volatility modules.
  
Check out the analysis of Theratechnologies Correlation against competitors.
For more information on how to buy Theratechnologies Stock please use our How to Invest in Theratechnologies guide.

Latest Theratechnologies' Ebitda Growth Pattern

Below is the plot of the Ebitda of Theratechnologies over the last few years. It is Theratechnologies' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theratechnologies' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Theratechnologies Ebitda Regression Statistics

Arithmetic Mean(7,170,247)
Coefficient Of Variation(117.98)
Mean Deviation6,107,273
Median(7,055,857)
Standard Deviation8,459,605
Sample Variance71.6T
Range32.4M
R-Value(0.56)
Mean Square Error53.3T
R-Squared0.31
Significance0.03
Slope(1,050,134)
Total Sum of Squares1001.9T

Theratechnologies Ebitda History

2024-12.5 M
2023-11.9 M
2022-10.3 M
2021-27.9 M
2020-17.2 M
2019-9.2 M
201840 K

About Theratechnologies Financial Statements

Theratechnologies investors use historical fundamental indicators, such as Theratechnologies' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theratechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-11.9 M-12.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theratechnologies Stock Analysis

When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.